Skip to main content

Incyte Corp(INCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low91.28
Day High93.64
Open:93.25
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Incyte Corp

Select a category then submit the form to load news
StockStory
2 Value Stocks to Consider Right Now and 1 We Ignore
BAND
Tipranks
Incyte’s Ruxolitinib Pediatric Leukemia Study Update: What Investors Should Watch
Tipranks
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing
StockStory
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?
INCY
Tipranks
Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)
Tipranks
Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion
Tipranks
Evercore ISI Remains a Hold on Incyte (INCY)
Tipranks
Guggenheim Remains a Buy on Incyte (INCY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY)
StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
KRT
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Option Care Health (OPCH)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Incyte (INCY) and Radnet (RDNT)
StockStory
3 S&P 500 Stocks to Target This Week
MCD
Motley Fool
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
Motley Fool
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
Tipranks
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Moderna (MRNA)
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Question
HTZ
GlobeNewswire
Registration Momentum Builds Across the Oncology Pipeline
StockStory
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call
INCY
Tipranks
Incyte’s Profit Outlook Threatened by Emerging U.S. ‘Most Favored Nation’ Drug Pricing Policies
Tipranks
Jefferies Keeps Their Buy Rating on Incyte (INCY)
Tipranks
Wells Fargo Remains a Hold on Incyte (INCY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Incyte (INCY) and Zimmer Biomet Holdings (ZBH)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Edwards Lifesciences (EW) and Royalty Pharma (RPRX)
Tipranks
Incyte Earnings Call Highlights Growth Beyond Jakafi
Zacks Investment Research
Company News for Feb 11, 2026
Company News for Feb 11, 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Incyte (INCY)
StockStory
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow
INCY
StockStory
Why Incyte (INCY) Stock Is Nosediving
INCY
Motley Fool
Incyte (INCY) Q4 2025 Earnings Call Transcript
StockStory
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales
INCY

Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.